Cardiovascular - Page 1

Sorbent initiates Phase IIb trial of CLP-1001 in heart failure patients
Friday, April 12, 2013 Biopharmaceutical company Sorbent Therapeutics has initiated a Phase IIb clinical trial of CLP-1001 to treat the signs and symptoms of fluid overload in heart failure...

Pivotal Vascazen-Reveal trial meets primary endpoint
Thursday, April 11, 2013 Specialty pharmaceutical company Pivotal Therapeutics has announced that its Vascazen - Reveal trial met its primary endpoint, the correction of omega-3...

Aastrom enrols first patients in ixCELL-DCM clinical trial
Friday, April 05, 2013 Aastrom Biosciences has enrolled the first patients in the ixCELL-DCM Phase IIb clinical trial of ixmyelocel-T in the...

Isis commences Phase I study of atherosclerosis drug
Thursday, April 04, 2013 Isis Pharmaceuticals has commenced a Phase I study to assess ISIS-APOARx for the treatment of...

Catabasis commences Phase I hypertriglyceridemia study of CAT-2003
Wednesday, March 27, 2013 Catabasis Pharmaceuticals has commenced a Phase I study of CAT-2003 for the treatment of severe hypertriglyceridemia in healthy volunteers and in adults with mildly elevated...

Pfizer REMINDER trial of Inspra meets primary composite efficacy endpoint
Tuesday, March 12, 2013 Pfizer has announced that its Reminder trial of Inspra (eplerenone) demonstrated statistically significant risk reductions, meeting its primary composite efficacy...

Adventrx to develop ANX-188 drug for acute limb ischemia
Monday, March 04, 2013 Adventrx Pharmaceuticals has announced plans to develop ANX-188 as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial...

Cardiorentis commences Phase III acute heart failure trial
Wednesday, February 13, 2013 Switzerland based Cardiorentis has commenced its Phase III trial of ularitide's efficacy and safety in patients with acute heart failure (TRUE-AHF) to evaluate the effect of early treatment...

FDA approves Kynamro injection for homozygous familial hypercholesterolemia
Thursday, January 31, 2013 The US FDA has approved orphan drug Kynamro (mipomersen sodium) injection for the treatment of homozygous familial hypercholesterolemia (HoFH), an inherited cholesterol...

Amgen Phase 3 Aranesp RED-HF trial fails to meet primary endpoint
Friday, January 18, 2013 Amgen has reported that Phase 3 Aranesp (darbepoetin alfa) RED-HF (reduction of events with darbepoetin alfa in heart failure) trial did not meet the primary endpoint of reducing the...

Stealth Peptides commences Phase II study of Bendavia for acute kidney injury (AKI)
Thursday, January 17, 2013 Biopharmaceutical company Stealth Peptides has commenced patient enrolment in the phase II study assessing Bendavia for the treatment of acute kidney injury (AKI) and renal...

Cardio3 BioSciences to initiate Phase III trial of heart failure stem cell therapy
Friday, November 23, 2012 Cardio3 BioSciences (C3BS) has obtained authorisation from the Belgian Federal Agency for Medicines and Health Products to commence its C3BS-CQR-1 Phase III heart failure trial in...

Xoma Phase III hypertension trial meets primary endpoint
Thursday, November 22, 2012 Xoma has reported that its fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate has met the primary endpoint in the Phase III perindopril amlodipine for the treatment...

Sanofi, Regeneron initiate Phase III cardiovascular outcomes trial
Tuesday, November 06, 2012 Sanofi and Regeneron Pharmaceuticals have announced the initiation of patient recruitment in a Phase III cardiovascular outcomes trial (CVOT) evaluating...

Bayer pulmonary hypertension drug shows efficacy in study
Thursday, October 25, 2012 Bayer HealthCare has reported positive results from a Phase III CHEST-1 trial of its investigational oral soluble guanylate cyclase (sGC)...

Resverlogix completes enrolment in ASSURE trial of RVX-208
Thursday, September 27, 2012 Resverlogix has finished enrolling high-risk cardiovascular disease patients in its 26-week, multi-centre, double-blind Phase IIb ASSURE trial of RVX-208, a BET protein...

Angion Biomedica begins Phase II heart attack trial with BB3
Friday, July 20, 2012 Angion Biomedica has initiated Phase II multicentre trial evaluating the safety of BB3 for the treatment of heart attack (acute myocardial infarction) in conjunction with standard-of-care and...

AstraZeneca to conduct EUCLID study of ticagrelor in PAD patients
Wednesday, July 18, 2012 UK-based AstraZeneca will begin the examining use of tiCagreLor in paD (EUCLID) study to evaluate the efficacy of ticagrelor compared with clopidogrel in reducing the primary endpoint, a...

Grifols reports positive Phase 1 safety, tolerability results for plasmin
Wednesday, June 13, 2012 Spain-based Grifols has announced positive Phase 1 safety and tolerability results for plasmin in treating patients with blood clots in the lower extremities, known as acute peripheral...

Actelion macitentan drug found to treat pulmonary arterial hypertension
Tuesday, May 01, 2012 Actelion has reported that its macitentan drug, a dual endothelin receptor antagonist, met its primary endpoint in a study involving 742 patients suffering from pulmonary arterial hypertension...